+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP)



Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP)



British Journal of Dermatology 176(6): 1599-1606



The enhanced liver fibrosis (ELF) test has been introduced to screen, diagnose and/or monitor liver conditions in large groups of patients with liver diseases. It has not been used in inflammatory skin or joint diseases. To evaluate the distribution of the ELF test, apply existing cut-offs for hepatic patients and healthy controls, and compare it with the procollagen-3 N-terminal peptide (P3NP) test in patients with psoriasis (PSO), psoriatic arthritis (PsA) and rheumatoid arthritis (RA), and controls. In total, 531 patients were included. Demographic, lifestyle and disease-specific data were collected. ELF and P3NP tests were performed. Prevalence of an increased ELF score (> 11) and P3NP was highest in patients with RA (7·7% and 6·1%, respectively) followed by patients with PSO (1·7% and 5·2%, respectively) and PsA (0·7% and 1·3%, respectively). Mean ± SD ELF scores for PSO, PsA and RA were, respectively, 9·09 ± 0·86, 8·96 ± 0·76 and 9·55 ± 1·04. All subgroups with moderate-to-severe disease severity had higher (> 9·8) ELF scores (PSO 27·0% vs. 18·3%; PsA 19·2% vs. 12%; RA 45·8% vs. 30·5%) and P3NP values. Distribution of the ELF score was smaller than the P3NP value [mean ± SD: 9·15 ± 0·92 (range 6·53-13·05) vs. 8·37 ± 4·30 (range 0·53-63·88)]. ELF score and P3NP are elevated in PSO, PsA and RA. ELF may be superior to P3NP alone, but further research should be done to validate the ELF test in determining susceptibility for developing liver fibrosis in PSO, PsA and RA.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057771845

Download citation: RISBibTeXText

PMID: 27925155

DOI: 10.1111/bjd.15220


Related references

Comparison of enhanced liver fibrosis test with procollagen-3 N-terminal peptide (P3NP) as a marker for liver fibrosis. British Journal of Dermatology 176(6): 1439-1440, 2017

Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. Journal of the American Academy of Dermatology 25(1 Pt 1): 50-53, 1991

Clinical features of psoriatic arthritis in Korean patients with psoriasis: a cross-sectional observational study of 196 patients with psoriasis using psoriatic arthritis screening questionnaires. Rheumatology International 36(2): 207-212, 2016

Procollagen type III N-terminal peptide (P3NP) and lean mass: a cross-sectional study. Journal of Frailty and Aging 2(3): 129-134, 2013

Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis. Journal of the American Academy of Dermatology 26(3 Pt 2): 509, 1992

Psoriasis and arthritis. III. A cross-sectional comparative study of patients with "psoriatic arthritis" and seronegative and seropositive polyarthritis: radiological and HLA aspects. Rheumatology International 4(2): 67-73, 1984

Psoriasis and arthritis 3. a cross sectional comparative study of patients with psoriatic arthritis and seronegative and seropositive polyarthritis radiological and hla aspects. Rheumatology International 4(2): 67-74, 1984

Psoriasis and arthritis 2. a cross sectional comparative study of patients with psoriatic arthritis and seronegative and seropositive polyarthritis clinical aspects. Rheumatology International 4(2): 61-66, 1984

Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study. Medicine 98(4): E13955, 2019

Comorbidities in patients with psoriatic arthritis: a comparison with rheumatoid arthritis and psoriasis. International Journal of Rheumatic Diseases 18(8): 873-879, 2015

THU0429The Risk of Incident Liver Disease among Patients with Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis: Table 1. Annals of the Rheumatic Diseases 75(Suppl 2): 344.3-345, 2016

Risk of Incident Liver Disease in Patients with Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis: A Population-Based Study. Journal of Investigative Dermatology 138(4): 760-767, 2018

Associations Between Five Important Domains of Health and the Patient Acceptable Symptom State in Rheumatoid Arthritis and Psoriatic Arthritis: A Cross-Sectional Study of 977 Patients. Arthritis Care and Research 69(10): 1504-1509, 2017

What is the ability of anti-cyclic citrullinated peptide antibodies determination in synovial fluid in discriminating rheumatoid arthritis from non-rheumatoid arthritis patients? A Tunisian cross-sectional study. Clinical Rheumatology 31(2): 375-379, 2012

Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey. Scandinavian Journal of Rheumatology 39(4): 303-309, 2010